Pharma

The event brings together industry leaders in Munich to explore how quality functions are evolving into strategic, risk-based and digitally enabled systems in response to increasing regulatory complexity and innovation in pharmaceuticals and biotechnology.

Collaboration aims to develop species-specific binders to accelerate research and improve control of zoonotic diseases.

From AI-enabled GPCR discovery to partnership-driven growth, Nxera is redefining how medicines are built and commercialised.

Tinlarebant becomes the first therapy to show clinical benefit in a pivotal global trial, reducing retinal lesion growth by 36% and paving the way for a planned FDA filing in 2026.

Long-term APEX results reinforce TREMFYA® as the only IL-23 inhibitor proven to slow structural joint damage in psoriatic arthritis.

A groundbreaking clinical trial set to begin in summer 2026 will test LungVax, the world’s first vaccine designed to prevent lung cancer in people at high risk, a major milestone in cancer prevention research.